Nektar Therapeutics to Participate in Two Investor Conferences in November
SAN FRANCISCO, Nov. 11, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Nektar Therapeutics to Participate in Two Investor Conferences in November
PR Newswire
SAN FRANCISCO, Nov. 11, 2026
SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences.
- UBS Global Biopharma Conference
- Format: Fireside Chat and 1×1 meetings
- Fireside Chat Date: Tuesday, November 17, 2026
- Fireside Chat Time: 11:20 – 11:50 a.m. GMT
- Location: London, UK
- Jefferies Global Healthcare Conference
- Format: Fireside Chat and 1×1 meetings
- Fireside Chat Date: Wednesday, November 18, 2026
- Fireside Chat Time: 8:00 – 8:25 a.m. GMT
- Location: London, UK
The live and archived webcasts will be accessible from the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events and replays will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar’s pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Contacts
For Investors:
Vivian Wu
628-895-0661
VWu@nektar.com
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
For Media:
Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-november-302936871.html
SOURCE Nektar Therapeutics
